null (Double Bond Pharmaceutical Int.) Aktie

Double Bond Pharmaceutical International AB (publ), a pharmaceutical company, engages in the development and commercialization of cancers and infectious diseases. It offers Temodex / SI053, a gel formulation of temozolomide for the local treatment of glioblastoma; SA-033, a novel treatment of cancers in liver; and SA-083 for the treatment of lung tumour. The company is also developing Belopenem for the treatment of bacterial pneumonia; and BeloGal, a drug delivery system based on biomimetic encapsulation of the active pharmaceutical ingredient with a polymer- and biology-free excipients. Double Bond Pharmaceutical International AB (publ) was incorporated in 2014 and is based in Uppsala, Sweden.